RINVOQ, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to DMARDs or who cannot tolerate them.
It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and:
• they have had 2 conventional DMARDs and at least 1 biological DMARD or
• TNF-alpha inhibitors are contraindicated but would otherwise be considered.
RINVOQ is recommended only if AbbVie provides it according to the commercial arrangement.